GHR Foundation’s Health Initiative is dedicated to a game-changing undertaking—the prevention of Alzheimer’s disease. The Foundation is targeting funding to improve some of the most important research efforts in the field, including Washington University's DIAN-TU Study. This trial focuses on rapid testing of prevention therapies among families that are most likely to develop the disease.
Recently, DIAN-TU announced it has completed participant enrollment for the first stage of the trial. This enrollment milestone means the first biomarker results will be available at the end of 2016, with the final cognitive endpoint expected in late 2019. This first stage will determine the effects of two drugs targeting amyloid plaques, which are believed by some scientists to be the first step in the process leading to cognitive impairment.
Recently, DIAN-TU announced it has completed participant enrollment for the first stage of the trial. This enrollment milestone means the first biomarker results will be available at the end of 2016, with the final cognitive endpoint expected in late 2019. This first stage will determine the effects of two drugs targeting amyloid plaques, which are believed by some scientists to be the first step in the process leading to cognitive impairment.
We will keep going until there are drugs to effectively prevent and treat Alzheimer’s disease.” –Dr. Randall Bateman, Washington University
The DIAN-TU team is working with the next generation of innovative drugs and study designs, and expects enrollment for new drugs. To learn more about DIAN-TU and GHR Foundation’s involvement in other innovative Alzheimer’s prevention trials, contact us.
RSS Feed
